Latest News and Press Releases

– Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments – – Carmot will join the Roche Group as part of Roche’s Pharmaceuticals...

– CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with overweight or obesity without type 2...

– Once-weekly administration of CT-388 delivers clinically meaningful weight loss and metabolic control with a favorable tolerability profile over a 4 week treatment period in overweight and obese...

– Proceeds to support development of Carmot's broad clinical-stage metabolic pipeline including two Phase 2 trials of CT-388, a once weekly, dual GLP-1/GIP receptor modulator for obese adults with and...

– A presentation on 4-week weight loss data from CT-388, a once weekly, dual GLP-1/GIP receptor modulator being developed for obese patients with and without type 2 diabetes – – Two presentations on...